ANIP has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANIP has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Days Inventory is also known as Days Sales of Inventory (DSI). ANI Pharmaceuticals's Average Total Inventories for the three months ended in Dec. 2023 was $108.9 Mil. ANI Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was $53.4 Mil. Hence, ANI Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 was 186.01.
The historical rank and industry rank for ANI Pharmaceuticals's Days Inventory or its related term are showing as below:
During the past 13 years, ANI Pharmaceuticals's highest Days Inventory was 300.60. The lowest was 147.58. And the median was 222.95.
ANI Pharmaceuticals's Days Inventory declined from Dec. 2022 (252.76) to Dec. 2023 (186.01).
Inventory Turnover measures how fast the company turns over its inventory within a year. ANI Pharmaceuticals's Inventory Turnover for the three months ended in Dec. 2023 was 0.49.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. ANI Pharmaceuticals's Inventory-to-Revenue for the three months ended in Dec. 2023 was 0.83.
The historical data trend for ANI Pharmaceuticals's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, ANI Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Drug Manufacturers industry and Healthcare sector, ANI Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where ANI Pharmaceuticals's Days Inventory falls into.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
ANI Pharmaceuticals's Days Inventory for the fiscal year that ended in Dec. 2023 is calculated as
Days Inventory (A: Dec. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (A: Dec. 2022 ) | + | Total Inventories (A: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (A: Dec. 2023 ) | * | Days in Period |
= | ( (105.355 | + | 111.196) | / | 2 ) | / | 181.513 | * | 365 |
= | 108.2755 | / | 181.513 | * | 365 | ||||
= | 217.73 |
ANI Pharmaceuticals's Days Inventory for the quarter that ended in Dec. 2023 is calculated as:
Days Inventory (Q: Dec. 2023 ) | |||||||||
= | Average Total Inventories | / | Cost of Goods Sold | * | Days in Period | ||||
= | ( (Total Inventories (Q: Sep. 2023 ) | + | Total Inventories (Q: Dec. 2023 )) | / | count ) | / | Cost of Goods Sold (Q: Dec. 2023 ) | * | Days in Period |
= | ( (106.59 | + | 111.196) | / | 2 ) | / | 53.42 | * | 365 / 4 |
= | 108.893 | / | 53.42 | * | 365 / 4 | ||||
= | 186.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANI Pharmaceuticals (NAS:ANIP) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
ANI Pharmaceuticals's Inventory Turnover for the three months ended in Dec. 2023 is calculated as
Inventory Turnover | = | Cost of Goods Sold | / | Average Total Inventories |
= | 53.42 | / | 108.893 | |
= | 0.49 |
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
ANI Pharmaceuticals's Inventory to Revenue for the three months ended in Dec. 2023 is calculated as
Inventory-to-Revenue | = | Average Total Inventories | / | Revenue |
= | 108.893 | / | 131.654 | |
= | 0.83 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Thank you for viewing the detailed overview of ANI Pharmaceuticals's Days Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Muthusamy Shanmugam | director, officer: HEAD OF R&D, COO-NOVITIUM OPS | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Meredith Cook | officer: SR. VP, GENERAL COUNSEL & SEC. | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Krista Davis | officer: SVP, CHIEF HR OFFICER | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Christopher Mutz | officer: HEAD OF RARE DISEASE | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Chad Gassert | officer: SVP - CORP. DEV. & STRATEGY | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Ori Gutwerg | officer: SVP, GENERICS | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
James G. Marken | officer: Vice President, Operations | 210 MAIN STREET WEST, C/O BIOSANTE PHARMACEUTICALS, INC., BAUDETTE MN 56623 |
Matthew J Leonard | director | 7 CUSTOM HOUSE STREET, PORTLAND ME 04101 |
Meridian Venture Partners Ii Lp | 10 percent owner | |
Nikhil Lalwani | director, officer: PRESIDENT & CEO | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623 |
Antonio R Pera | director | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET, BAUDETTE MN 56623 |
Stephen P. Carey | officer: Vice President and CFO | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Renee P Tannenbaum | director | 9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054 |
Jeanne Thoma | director | C/O ANI PHARMACEUTICALS, INC., 210 MAIN STREET WEST, BAUDETTE MN 56623 |
Patrick D Walsh | director | 14282 FRANKLIN AVE., TUSTIN CA 92780 |
From GuruFocus
By Marketwired • 08-09-2023
By Business Wire Business Wire • 08-03-2022
By Marketwired • 07-31-2023
By Marketwired • 09-12-2023
By Business Wire Business Wire • 04-24-2023
By Business Wire Business Wire • 07-28-2022
By Business Wire Business Wire • 11-28-2022
By Marketwired • 10-30-2023
By Business Wire Business Wire • 05-22-2023
By Business Wire Business Wire • 08-30-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.